Our results showed that the killing of Vγ9Vδ2 T cells against primary glioma cells was significantly enhanced after ZOL (Fig. 3A) or BTN3A1 agonistic antibody stimulation (Fig. 3B). This evidence concerns the gene BTN3A1 and glioma.